Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old wh...
Read more -
GSK to present data from its innovative oncology portfolio at ESMO Congress 2019
GSK today announced that data from its growing oncology pipeline will be presented at the European Society for Medical Oncology Congress in Barcelona, Spain, September 27 - Octo...
Read more -
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
Belantamab mafodotin (GSK2857916) on track for regulatory submission by the end of 2019
Read more -
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration.
Read more -
GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing appr...
Read more -
GSK announces leadership changes in the US
GSK today announced that Jack Bailey, President US Pharmaceuticals has decided to step down from his role at the end of the year. Bailey will be succeeded by Maya Martinez-Davis...
Read more -
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
Read more -
Nucala receives EU approval for self-administration by patients with severe eosinophilic asthma
96% of patients in studies preferred self-administration at home over being treated in clinic
Read more -
GSK completes transaction with Pfizer to form new world-leading Consumer Healthcare Joint Venture
GlaxoSmithKline plc today announced that it has completed its transaction with Pfizer to combine their consumer healthcare businesses into a world-leading Joint Venture.
Read more -
Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements
Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe
Read more -
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
The marketing application is based on phase III ATLAS and FLAIR pivotal trials in which the once-monthly, injectable treatment regimen showed similar efficacy and safety to dail...
Read more -
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of...
Read more -
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) demonstrate non-inferior efficacy of Dovato▼ (dolutegravir/lamivu...
Read more -
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
Read more -
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
Read more -
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
Read more -
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data to be presented span the company’s diverse portfolio, challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living w...
Read more -
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
Read more -
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
Read more -
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
